Scientists have created an experimental vaccine using modified bacteria that could help the body fight cancer.
An innovative vaccine opens new perspectives in the treatment of tumors. Photo: The Truth Archive
Bacterial-based personalized vaccines represent a new frontier in cancer immunotherapy, offering an innovative therapeutic approach for cancer patients.
Columbia University researchers have developed genetically engineered probiotics capable of inducing a specific anti-tumor immune response. These bacteria act as efficient vectors for the delivery of tumor antigens, stimulating strong and durable antitumor immunity.
By genetically modifying microbes, we can create vaccines capable of stimulating a specific immune response against each patient’s unique tumor antigens, thus reducing the risk of relapse.
In a groundbreaking experiment, scientists used specially modified bacteria to treat mice with serious forms of cancer, such as colon and melanoma. The results were amazing: the mice’s immune system was so stimulated that it was able to stop the growth of tumors, and in many cases, even destroy them completely, without harming healthy tissues.
These findings were published in the journal Nature.
Researchers have discovered a new weapon in the fight against cancer: genetically modified bacteria. These have been shown to be much more powerful than traditional treatments, offering hope for faster and more effective healing.
Dr. Andrew Redenti, PhD student at Columbia University’s Vagelos College of Medicine and Surgery, who contributed to the study, said: “The important advantage of our system is its unique ability to restructure and coordinately activate all arms of the immune system to induce a productive antitumor immune response. We believe this is why the system works so well in advanced solid tumor models that have been particularly difficult to treat with other immunotherapies.”
Good news for cancer patients! A team of researchers, led by Jongwon Im from Columbia University, has created a bacterial vaccine that can defeat even the most aggressive forms of cancer, as animal experiments have shown. This innovative treatment offers hope for a new era in cancer therapy.
Just as no two people are alike, no two tumors are alike. This is precisely why this new vaccine is genetically tailored to target the specific mutations of each patient’s tumor, offering a personalized therapeutic approach.
“By programming bacteria that direct the immune system to target these cancer-specific mutations, we can develop more effective therapies that stimulate the patient’s own immune system to detect and kill cancer cells. As we continue to integrate additional safety optimizations through additional genetic programming, we are getting closer to testing this therapy in patients,” he explains. Nicholas Arpaia, associate professor of microbiology and immunology at Vagelos College, who led the research.
An amazing medical discovery, over a century old, shows us that bacteria could be our allies in the fight against cancer. As early as the 19th century, doctors noticed that injections of certain bacteria could make tumors shrink. Today, this idea is again in the focus of researchers, who are exploring ways to use genetically modified bacteria to attack tumors in a more precise and effective way. But used in this way, the bacteria do not usually control or precisely direct the immune response to attack the cancer.
Nicholas Arpaia says: “These qualities do not give the bacteria enough power to stimulate immune responses capable of destroying a tumor, but they represent a good starting point for building a new field of cancer therapy.”
Immunotherapy with live bacteria represents a new frontier in oncology. By customizing the antigenic profile of the bacteria according to tumor specificity, it is possible to induce a strong and durable antitumor immune response, thus improving the prognosis of patients. Researchers have genetically modified E. coli bacteria to produce tumor-specific proteins.
Tumors are smart and have their own tricks to avoid being detected by our immune system. But these special bacteria are even smarter! They not only signal the presence of the tumor, but also manage to override the tumor’s defense mechanisms, making it vulnerable to immune system attack.
To ensure the safety of this therapy, the genetically modified bacteria are designed to be immunogenic so that they can be rapidly cleared by the immune system in the absence of a persistent antigenic stimulus, such as a tumor.
Animal experiments have shown that these vaccines stimulate a strong and complex immune response directed both at destroying tumor cells and at inhibiting tumor immunosuppressive mechanisms. The vaccine has shown promise both in preventing cancer, reducing the growth of tumors in unaffected mice, and in preventing relapses in those already affected.
In humans, developing these microbial vaccines would involve sequencing a patient’s tumor to identify unique neoantigens, followed by genetically engineering the bacteria to mass-produce these neoantigens and other immunomodulatory factors, which, once infused, would migrate to the tumor, activating the immune system to eliminate both primary tumors and metastases.
Since each tumor has its own set of neoantigens, immunotherapy will be personalized for each patient. “The length of time until treatment will depend primarily on how long it takes to sequence the tumor. Then we just have to produce the bacterial strains, which can be quite fast. The bacteria may be simpler to manufacture than other vaccine platforms,” explains Prof. Tal Danino, from Columbia University, who made a significant contribution to this research project.
The bacteria are programmed to recognize and specifically target tumor mutations, thereby limiting the ability of cancer cells to develop resistance and spread. “Because our platform allows us to deliver so many different neoantigens, it theoretically becomes difficult for tumor cells to lose all of these targets at once and avoid the immune response”Prof. Arpaia adds.
While traditional cancer vaccines have limitations in modulating the immunosuppressive tumor microenvironment, these bacteria offer a more comprehensive approach, combining immune stimulation with direct tumor modification. “Bacteria allow the administration of a higher concentration of drugs than can be tolerated when these compounds are administered systemically throughout the body. Here, we can limit administration directly to the tumor and locally modulate the way we stimulate the immune system,” explains Prof. Arpaia.
